
GHRS Stock Forecast & Price Target
GHRS Analyst Ratings
Bulls say
GH Research is viewed positively because its lead program GH001 has already shown unusually strong Phase IIb efficacy in TRD, including a -15.5 point placebo-adjusted MADRS reduction at Day 8, 57.5% remission at Day 8 versus 0% on placebo, and 73% remission at 6 months. The company also has multiple de-risking catalysts, as July 2026 FDA feedback indicated its CMC and proprietary aerosol device plans appear Phase III ready, while its patent was upheld in Europe and U.S. proceedings remain ongoing. With Phase III site selection completed, pivotal doses chosen, and a pathway that may avoid repeated visits and a licensed psychotherapist, the execution profile and commercialization potential look compelling despite regulatory risks.
Bears say
GH Research is facing a highly uncertain investment case because GH001 remains under a clinical hold, and the FDA may refuse to lift it, require additional information, or object to the Phase III design, including the Day 8 endpoint and IDR replication. Even if development proceeds, the company still faces the risk that efficacy seen in earlier studies will not be reproduced in the registrational Phase III trial, while safety, tolerability, or inhalation-device manufacturing issues could halt the program. Commercially, it may struggle with DEA rescheduling, slower real-world adoption, and financing needs for Phase III and any eventual launch, all of which are especially concerning for a single-segment R&D company.
This aggregate rating is based on analysts' research of GH Research PLC and is not a guaranteed prediction by Public.com or investment advice.
GHRS Analyst Forecast & Price Prediction
Start investing in GHRS
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About GH Research PLC (GHRS) Forecast
GHRS Analyst Forecast & Price Prediction
Start investing in GHRS
Order type
Buy in
Order amount
Est. shares
0 shares